<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>0300-9041</journal-id>
<journal-title><![CDATA[Ginecología y obstetricia de México]]></journal-title>
<abbrev-journal-title><![CDATA[Ginecol. obstet. Méx.]]></abbrev-journal-title>
<issn>0300-9041</issn>
<publisher>
<publisher-name><![CDATA[Federación Mexicana de Colegios de Obstetricia y Ginecología A.C.]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S0300-90412019000600379</article-id>
<article-id pub-id-type="doi">10.24245/gom.v87i6.3025</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Hierro carboximaltosa por vía intravenosa para tratamiento de la anemia ferropénica en pacientes con hemorragia uterina anormal]]></article-title>
<article-title xml:lang="en"><![CDATA[Intravenous ferric carboxymaltose injection for treatment iron deficiency anemia in abnormal uterine bleeding]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Valderrama-Loyola]]></surname>
<given-names><![CDATA[Omar]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Villacorta-Argaez]]></surname>
<given-names><![CDATA[Alfredo]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Río de la Loza-Jiménez]]></surname>
<given-names><![CDATA[Fernando]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Hospital Río de la Loza  ]]></institution>
<addr-line><![CDATA[Naucalpan Estado de México]]></addr-line>
<country>Mexico</country>
</aff>
<aff id="Af2">
<institution><![CDATA[,Hospital Río de la Loza  ]]></institution>
<addr-line><![CDATA[Naucalpan Estado de México]]></addr-line>
</aff>
<aff id="Af3">
<institution><![CDATA[,Hospital Río de la Loza  ]]></institution>
<addr-line><![CDATA[Naucalpan Estado de México]]></addr-line>
<country>Mexico</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>00</month>
<year>2019</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>00</month>
<year>2019</year>
</pub-date>
<volume>87</volume>
<numero>6</numero>
<fpage>379</fpage>
<lpage>384</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_arttext&amp;pid=S0300-90412019000600379&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_abstract&amp;pid=S0300-90412019000600379&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_pdf&amp;pid=S0300-90412019000600379&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[Resumen  OBJETIVO: Evaluar la eficacia y seguridad de la administración de altas dosis de hierro carboximaltosa en el tratamiento de pacientes con anemia ferropénica secundaria a hemorragia uterina anormal.  MATERIAL Y MÉTODOS:  Estudio cuasiexperimental de intervención, no controlado, con la variedad antes y después de un solo grupo (pretest-postest) efectuado en el Hospital Río de la Loza entre mayo de 2014 y septiembre de 2018. Criterios de inclusión: pacientes de 18 años o mayores con anemia y hemorragia uterina anormal severa. Criterios de exclusión: transfusión de concentrados eritrocitarios o administración de hierro parenteral en las ocho semanas previas al estudio, etc. Variables de estudio: hemoglobina, hematocrito, volumen corpuscular medio, concentración de hemoglobina corpuscular media, plaquetas y concentraciones de ferritina y plaquetas.  RESULTADOS: Se analizaron los datos de 18 pacientes con anemia ferropénica secundaria a hemorragia uterina anormal 13 de 18 experimentaron un incremento de 2 g/dL o mayor de hemoglobina , 9 de 18 obtuvieron un incremento de 2.5 o mayor y solo 7 de 18 obtuvieron un incremento de 3 g/dL o mayor, los incrementos fueron dependientes de las dosis administrada. La ferritina sérica final promedio fue de 33.44 mcg/L. No hubo efectos adversos graves reportados.  CONCLUSIONES: En este grupo de pacientes con anemia ferropénica, la administración de hierro carboximaltosa por vía intravenosa a dosis altas fue segura en la corrección de la carencia del mineral secundaria a hemorragia uterina anormal y en el reabastecimiento de los depósitos de hierro.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[Abstract  OBJECTIVE: The objective was to evaluate efficacy and safety of rapid, large-dose intravenous (IV) administration of ferric carboxymaltose in correcting iron deficiency anemia due to abnormal uterine bleeding.  MATERIAL AND METHODS:  Quasi-experimental study of intervention, not controlled, with the variety before and after a single group (pretest-posttest) carried out in the Hospital Río de la Loza, Mexico, between May 2014 and September 2018. Inclusion criteria: patients 18 years of age or older with anemia and severe abnormal uterine hemorrhage. Exclusion criteria: transfusion of erythrocyte concentrates or administration of parenteral iron in the eight weeks prior to the study, etc. Study variables: hemoglobin, hematocrit, mean corpuscular volume, mean corpuscular hemoglobin concentration, platelets and concentrations of ferritin and platelets.  RESULTS: 13 patients of 18 obtained an increase of 2 g/dL or greater of hemoglobin, 9 of 18 obtained an increase of 2.5 or greater and only 7 of 18 obtained an increase of 3g/dL or greater, the increases were dependent on the administered dose. The average final serum ferritin was 33.44 mcg/L. There were no serious adverse effects reported.  CONCLUSIONS: The use of iron carboxymaltose intravenously at high doses is a safe treatment in the correction of iron deficiency anemia secondary to abnormal uterine hemorrhage and in the replenishment of iron stores.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[Carboximaltosa férrica]]></kwd>
<kwd lng="es"><![CDATA[anemia por deficiencia de hierro]]></kwd>
<kwd lng="es"><![CDATA[hemorragia uterina]]></kwd>
<kwd lng="es"><![CDATA[eritrocitos]]></kwd>
<kwd lng="es"><![CDATA[hierro parenteral]]></kwd>
<kwd lng="es"><![CDATA[compuestos férricos]]></kwd>
<kwd lng="en"><![CDATA[Ferric carboxymaltose]]></kwd>
<kwd lng="en"><![CDATA[Iron deficiency anemia]]></kwd>
<kwd lng="en"><![CDATA[Uterine hemorrhage]]></kwd>
<kwd lng="en"><![CDATA[Erythrocyte]]></kwd>
<kwd lng="en"><![CDATA[Parenteral iron]]></kwd>
<kwd lng="en"><![CDATA[Ferric compounds]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Cook]]></surname>
<given-names><![CDATA[JD]]></given-names>
</name>
<name>
<surname><![CDATA[Flowers]]></surname>
<given-names><![CDATA[CH]]></given-names>
</name>
<name>
<surname><![CDATA[Skikne]]></surname>
<given-names><![CDATA[BS]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The quantitative assessment of body iron]]></article-title>
<source><![CDATA[Blood]]></source>
<year>2003</year>
<volume>9</volume>
<page-range>3359-64</page-range></nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="journal">
<collab>Centers for Disease Control and Prevention</collab>
<article-title xml:lang=""><![CDATA[Iron deficiency-United States, 1999-2000]]></article-title>
<source><![CDATA[MMWR Morb Mortal Wkly Rep]]></source>
<year>2002</year>
<volume>51</volume>
<page-range>897-9</page-range></nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Learman]]></surname>
<given-names><![CDATA[LA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Hysterectomy versus expanded medical treatment for abnormal uterine bleeding: clinical outcomes in the medicine or surgery trial]]></article-title>
<source><![CDATA[Obstet Gynecol]]></source>
<year>2004</year>
<volume>103</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>824-33</page-range></nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Carlson]]></surname>
<given-names><![CDATA[KJ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The Maine Women&#8217;s Health Study: II. Outcomes of nonsurgical management of leiomyomas, abnormal bleeding, and chronic pelvic pain]]></article-title>
<source><![CDATA[Obstet Gynecol]]></source>
<year>1994</year>
<volume>83</volume>
<page-range>566-72</page-range></nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Varner]]></surname>
<given-names><![CDATA[RE]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Medicine or surgery (Ms): a randomized clinical trial comparing hysterectomy and medical treatment in premenopausal women with abnormal uterine bleeding]]></article-title>
<source><![CDATA[Control Clin Trials]]></source>
<year>2004</year>
<volume>25</volume>
<page-range>104-18</page-range></nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Crichton]]></surname>
<given-names><![CDATA[RR]]></given-names>
</name>
</person-group>
<source><![CDATA[Iron Therapy with Special Emphasis on Intravenous Administration]]></source>
<year>2008</year>
<publisher-loc><![CDATA[London ]]></publisher-loc>
<publisher-name><![CDATA[UNI-MED]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hurrell]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Egli]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Iron bioavailability and dietary reference values]]></article-title>
<source><![CDATA[Am J Clin Nutr]]></source>
<year>2010</year>
<volume>91</volume>
<numero>5</numero>
<issue>5</issue>
</nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Nairz]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Iron deficiency or anemia of inflammation? Differential diagnosis and mechanisms of anemia of inflammation]]></article-title>
<source><![CDATA[Wien Med Wochenschr]]></source>
<year>2016</year>
<volume>166</volume>
<numero>13-14</numero>
<issue>13-14</issue>
<page-range>411-23</page-range></nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kassebaum]]></surname>
<given-names><![CDATA[NJ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[A systematic analysis of global anemia burden from 1990 to 2010]]></article-title>
<source><![CDATA[Blood]]></source>
<year>2014</year>
<volume>123</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>615-24</page-range></nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="journal">
<collab>Global Burden of Disease Study 2013 Collaborators</collab>
<article-title xml:lang=""><![CDATA[Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013]]></article-title>
<source><![CDATA[Lancet]]></source>
<year>2015</year>
<volume>386</volume>
<numero>9995</numero>
<issue>9995</issue>
<page-range>743-800</page-range></nlm-citation>
</ref>
<ref id="B11">
<label>11</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Camaschella]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Iron-deficiency anemia]]></article-title>
<source><![CDATA[N Engl J Med]]></source>
<year>2015</year>
<volume>372</volume>
<numero>19</numero>
<issue>19</issue>
<page-range>1832-43</page-range></nlm-citation>
</ref>
<ref id="B12">
<label>12</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Enjuanes]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Iron deficiency and health-related quality of life in chronic heart failure: results from a multicenter European study]]></article-title>
<source><![CDATA[Int J Cardiol]]></source>
<year>2014</year>
<volume>174</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>268-75</page-range></nlm-citation>
</ref>
<ref id="B13">
<label>13</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Haas]]></surname>
<given-names><![CDATA[JD]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Iron deficiency and reduced work capacity: a critical review of the research to determine a causal relationship]]></article-title>
<source><![CDATA[J Nutr]]></source>
<year>2001</year>
<volume>131</volume>
<numero>2S-2</numero>
<issue>2S-2</issue>
<page-range>676S-90S</page-range></nlm-citation>
</ref>
<ref id="B14">
<label>14</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Patterson]]></surname>
<given-names><![CDATA[AJ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Iron deficiency, general health and fatigue: results from the Australian Longitudinal Study on Women&#8217;s Health]]></article-title>
<source><![CDATA[Qual Life Res]]></source>
<year>2000</year>
<volume>9</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>491-7</page-range></nlm-citation>
</ref>
<ref id="B15">
<label>15</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hentze]]></surname>
<given-names><![CDATA[MW]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Two to tango: regulation of Mammalian iron metabolism]]></article-title>
<source><![CDATA[Cell]]></source>
<year>2010</year>
<volume>142</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>24-38</page-range></nlm-citation>
</ref>
<ref id="B16">
<label>16</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Peyrin-Biroulet]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Guidelines on the diagnosis and treatment of iron deficiency across indications: a systematic review]]></article-title>
<source><![CDATA[Am J Clin Nutr]]></source>
<year>2015</year>
<volume>102</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>1585-94</page-range></nlm-citation>
</ref>
<ref id="B17">
<label>17</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Brugnara]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Beris]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Iron therapy. In: Beaumont C, Béris P, Beuzard Y, Brugnara C, eds. ESH Handbook on Disorders of Iron Metabolism. Paris]]></article-title>
<source><![CDATA[European School of Haematology]]></source>
<year>2009</year>
<page-range>512-28</page-range></nlm-citation>
</ref>
<ref id="B18">
<label>18</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hallberg]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Side-effects of oral iron therapy: a comparative trial of different iron compounds in tablet form]]></article-title>
<source><![CDATA[Acta Med Scand]]></source>
<year>1966</year>
<volume>181</volume>
<numero>^sSuppl 459</numero>
<issue>^sSuppl 459</issue>
<supplement>Suppl 459</supplement>
<page-range>S3-10</page-range></nlm-citation>
</ref>
<ref id="B19">
<label>19</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Moore]]></surname>
<given-names><![CDATA[RA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Meta-analysis of efficacy and safety of intravenous ferric carboxymaltose (Ferinject) from clinical trial reports and published trial data]]></article-title>
<source><![CDATA[BMC Blood Disord]]></source>
<year>2011</year>
<volume>11</volume>
<numero>4</numero>
<issue>4</issue>
</nlm-citation>
</ref>
<ref id="B20">
<label>20</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Gisbert]]></surname>
<given-names><![CDATA[JP]]></given-names>
</name>
<name>
<surname><![CDATA[Gomollón]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Common misconceptions in the diagnosis and management of anemia in inflammatory bowel disease]]></article-title>
<source><![CDATA[Am J Gastroenterol]]></source>
<year>2008</year>
<volume>103</volume>
<page-range>1299-307</page-range></nlm-citation>
</ref>
<ref id="B21">
<label>21</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bailie]]></surname>
<given-names><![CDATA[GR]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Hypersensitivity reactions and deaths associated with intravenous iron preparations]]></article-title>
<source><![CDATA[Nephrol Dial Transplant]]></source>
<year>2005</year>
<volume>20</volume>
<page-range>1443-9</page-range></nlm-citation>
</ref>
<ref id="B22">
<label>22</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Walters]]></surname>
<given-names><![CDATA[BA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Benchmarking iron dextran sensitivity: reactions requiring resuscitative medication in incident and prevalent patients]]></article-title>
<source><![CDATA[Nephrol Dial Transplant]]></source>
<year>2005</year>
<volume>20</volume>
<page-range>1438-42</page-range></nlm-citation>
</ref>
<ref id="B23">
<label>23</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[VanWyck]]></surname>
<given-names><![CDATA[DB]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Labile iron: manifestations and clinical implications]]></article-title>
<source><![CDATA[J Am Soc Nephrol]]></source>
<year>2004</year>
<volume>15</volume>
<numero>^sSuppl 2</numero>
<issue>^sSuppl 2</issue>
<supplement>Suppl 2</supplement>
<page-range>S107-11</page-range></nlm-citation>
</ref>
<ref id="B24">
<label>24</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Brookhart]]></surname>
<given-names><![CDATA[MA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Comparative mortality risk of anemia management practices in incident hemodialysis patients]]></article-title>
<source><![CDATA[JAMA]]></source>
<year>2010</year>
<volume>303</volume>
<page-range>857-64</page-range></nlm-citation>
</ref>
<ref id="B25">
<label>25</label><nlm-citation citation-type="">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Folb]]></surname>
<given-names><![CDATA[PI]]></given-names>
</name>
</person-group>
<source><![CDATA[The safety of iron dextran and a comparison with iron sucrose for intravenous use: a short report to the world health organization advisory committee on the safety of medicines]]></source>
<year></year>
</nlm-citation>
</ref>
<ref id="B26">
<label>26</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[VanWyck]]></surname>
<given-names><![CDATA[DB]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Intravenous ferric carboxymaltose compared with oral iron in the treatment of postpartum anemia: a randomized controlled trial]]></article-title>
<source><![CDATA[Obstet Gynecol]]></source>
<year>2007</year>
<volume>110</volume>
<page-range>267-78</page-range></nlm-citation>
</ref>
<ref id="B27">
<label>27</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lyseng-Williamson]]></surname>
<given-names><![CDATA[KA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Ferric carboxymaltose: a review of its use in iron-deficiency anaemia]]></article-title>
<source><![CDATA[Drugs]]></source>
<year>2009</year>
<volume>69</volume>
<page-range>739-56</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
